This company has been marked as potentially delisted and may not be actively trading.

Vermillion (VRML) Competitors

VRML vs. NAVB, VANI, CO, NYXH, and PEPG

Should you be buying Vermillion stock or one of its competitors? The main competitors of Vermillion include Navidea Biopharmaceuticals (NAVB), Vivani Medical (VANI), Global Cord Blood (CO), Nyxoah (NYXH), and PepGen (PEPG). These companies are all part of the "medical" sector.

How does Vermillion compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Vermillion (NASDAQ:VRML) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

: 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 18.1% of Vermillion shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 4.4% of Vermillion shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Vermillion'saverage media sentiment score.
Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Vermillion Neutral
: Navidea Biopharmaceuticals has higher earnings, but lower revenue than Vermillion.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Navidea Biopharmaceuticals $8.13K 0.00 -$15.18M -$0.21 N/A
Vermillion $4.54M 6.43 -$15.24M N/A N/A
: Navidea Biopharmaceuticals has a net margin of 0.00% compared to Vermillion's net margin of -307.31%. Navidea Biopharmaceuticals' return on equity of 0.00% beat Vermillion's return on equity.
Company Net Margins Return on Equity Return on Assets
Navidea Biopharmaceuticals N/A N/A N/A
Vermillion -307.31% -155.25% -103.47%
: Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, Vermillion has a beta of 3.47, suggesting that its stock price is 247% more volatile than the S&P 500.

Company	Overall Sentiment
Navidea Biopharmaceuticals	Neutral
Vermillion	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A
Vermillion	$4.54M	6.43	-$15.24M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Navidea Biopharmaceuticals	N/A	N/A	N/A
Vermillion	-307.31%	-155.25%	-103.47%

Summary

Navidea Biopharmaceuticals beats Vermillion on 6 of the 9 factors compared between the two stocks.

How does Vermillion compare to Vivani Medical?

Vermillion (NASDAQ:VRML) and Vivani Medical (NASDAQ:VANI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

: Vivani Medical has a consensus target price of $3.50, suggesting a potential upside of 180.00%. Given Vivani Medical's stronger consensus rating and higher probable upside, analysts clearly believe Vivani Medical is more favorable than Vermillion.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vermillion
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Vivani Medical
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: 18.1% of Vermillion shares are owned by institutional investors. Comparatively, 6.8% of Vivani Medical shares are owned by institutional investors. 4.4% of Vermillion shares are owned by insiders. Comparatively, 46.4% of Vivani Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: Vivani Medical has a net margin of 0.00% compared to Vermillion's net margin of -307.31%. Vermillion's return on equity of -155.25% beat Vivani Medical's return on equity.
Company Net Margins Return on Equity Return on Assets
Vermillion -307.31% -155.25% -103.47%
Vivani Medical N/A -317.03% -82.64%
: Vermillion has a beta of 3.47, suggesting that its share price is 247% more volatile than the S&P 500. Comparatively, Vivani Medical has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500.
: In the previous week, Vivani Medical had 1 more articles in the media than Vermillion. MarketBeat recorded 1 mentions for Vivani Medical and 0 mentions for Vermillion. Vermillion's average media sentiment score of 0.00 equaled Vivani Medical'saverage media sentiment score.
Company Overall Sentiment
Vermillion Neutral
Vivani Medical Neutral
: Vermillion has higher revenue and earnings than Vivani Medical.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vermillion $4.54M 6.43 -$15.24M N/A N/A
Vivani Medical N/A N/A -$26.61M -$0.43 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vermillion	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
Vermillion	-307.31%	-155.25%	-103.47%
Vivani Medical	N/A	-317.03%	-82.64%

Company	Overall Sentiment
Vermillion	Neutral
Vivani Medical	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vermillion	$4.54M	6.43	-$15.24M	N/A	N/A
Vivani Medical	N/A	N/A	-$26.61M	-$0.43	N/A

Summary

Vivani Medical beats Vermillion on 7 of the 13 factors compared between the two stocks.

How does Vermillion compare to Global Cord Blood?

Global Cord Blood (NYSE:CO) and Vermillion (NASDAQ:VRML) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

: Global Cord Blood has a net margin of 0.00% compared to Vermillion's net margin of -307.31%. Global Cord Blood's return on equity of 0.00% beat Vermillion's return on equity.
Company Net Margins Return on Equity Return on Assets
Global Cord Blood N/A N/A N/A
Vermillion -307.31% -155.25% -103.47%
: Global Cord Blood has a beta of 0.16, suggesting that its stock price is 84% less volatile than the S&P 500. Comparatively, Vermillion has a beta of 3.47, suggesting that its stock price is 247% more volatile than the S&P 500.
: 18.1% of Vermillion shares are owned by institutional investors. 0.5% of Global Cord Blood shares are owned by insiders. Comparatively, 4.4% of Vermillion shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
: Global Cord Blood has higher revenue and earnings than Vermillion.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Global Cord Blood $1.24B 0.09 $79.04M $0.64 1.49
Vermillion $4.54M 6.43 -$15.24M N/A N/A
: In the previous week, Global Cord Blood had 1 more articles in the media than Vermillion. MarketBeat recorded 1 mentions for Global Cord Blood and 0 mentions for Vermillion. Global Cord Blood's average media sentiment score of 0.00 equaled Vermillion'saverage media sentiment score.
Company Overall Sentiment
Global Cord Blood Neutral
Vermillion Neutral

Company	Net Margins	Return on Equity	Return on Assets
Global Cord Blood	N/A	N/A	N/A
Vermillion	-307.31%	-155.25%	-103.47%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Cord Blood	$1.24B	0.09	$79.04M	$0.64	1.49
Vermillion	$4.54M	6.43	-$15.24M	N/A	N/A

Company	Overall Sentiment
Global Cord Blood	Neutral
Vermillion	Neutral

Summary

Global Cord Blood beats Vermillion on 7 of the 11 factors compared between the two stocks.

How does Vermillion compare to Nyxoah?

Nyxoah (NASDAQ:NYXH) and Vermillion (NASDAQ:VRML) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

: 18.1% of Vermillion shares are owned by institutional investors. 4.4% of Vermillion shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: In the previous week, Nyxoah had 3 more articles in the media than Vermillion. MarketBeat recorded 3 mentions for Nyxoah and 0 mentions for Vermillion. Nyxoah's average media sentiment score of 0.00 equaled Vermillion'saverage media sentiment score.
Company Overall Sentiment
Nyxoah Neutral
Vermillion Neutral
: Vermillion has lower revenue, but higher earnings than Nyxoah.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nyxoah $11.33M 10.16 -$101.92M -$2.68 N/A
Vermillion $4.54M 6.43 -$15.24M N/A N/A
: Vermillion has a net margin of -307.31% compared to Nyxoah's net margin of -884.69%. Nyxoah's return on equity of -139.18% beat Vermillion's return on equity.
Company Net Margins Return on Equity Return on Assets
Nyxoah -884.69% -139.18% -79.53%
Vermillion -307.31% -155.25% -103.47%
: Nyxoah currently has a consensus price target of $9.33, indicating a potential upside of 214.25%. Given Nyxoah's stronger consensus rating and higher probable upside, equities research analysts clearly believe Nyxoah is more favorable than Vermillion.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nyxoah
1 Sell rating(s)
0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
Vermillion
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Nyxoah has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Comparatively, Vermillion has a beta of 3.47, meaning that its share price is 247% more volatile than the S&P 500.

Company	Overall Sentiment
Nyxoah	Neutral
Vermillion	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33M	10.16	-$101.92M	-$2.68	N/A
Vermillion	$4.54M	6.43	-$15.24M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-884.69%	-139.18%	-79.53%
Vermillion	-307.31%	-155.25%	-103.47%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vermillion	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Nyxoah beats Vermillion on 9 of the 14 factors compared between the two stocks.

How does Vermillion compare to PepGen?

PepGen (NASDAQ:PEPG) and Vermillion (NASDAQ:VRML) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

: 58.0% of PepGen shares are owned by institutional investors. Comparatively, 18.1% of Vermillion shares are owned by institutional investors. 4.6% of PepGen shares are owned by insiders. Comparatively, 4.4% of Vermillion shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: In the previous week, PepGen had 2 more articles in the media than Vermillion. MarketBeat recorded 2 mentions for PepGen and 0 mentions for Vermillion. PepGen's average media sentiment score of 0.62 beat Vermillion's score of 0.00 indicating that PepGen is being referred to more favorably in the media.
Company Overall Sentiment
PepGen Positive
Vermillion Neutral
: Vermillion has higher revenue and earnings than PepGen.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PepGen N/A N/A -$89.65M -$2.41 N/A
Vermillion $4.54M 6.43 -$15.24M N/A N/A
: PepGen has a net margin of 0.00% compared to Vermillion's net margin of -307.31%. PepGen's return on equity of -75.73% beat Vermillion's return on equity.
Company Net Margins Return on Equity Return on Assets
PepGen N/A -75.73% -60.42%
Vermillion -307.31% -155.25% -103.47%
: PepGen currently has a consensus price target of $11.80, indicating a potential upside of 511.40%. Given PepGen's stronger consensus rating and higher probable upside, equities research analysts clearly believe PepGen is more favorable than Vermillion.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PepGen
1 Sell rating(s)
0 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.67
Vermillion
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: PepGen has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500. Comparatively, Vermillion has a beta of 3.47, meaning that its share price is 247% more volatile than the S&P 500.

Company	Overall Sentiment
PepGen	Positive
Vermillion	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$2.41	N/A
Vermillion	$4.54M	6.43	-$15.24M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-75.73%	-60.42%
Vermillion	-307.31%	-155.25%	-103.47%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Vermillion	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

PepGen beats Vermillion on 11 of the 14 factors compared between the two stocks.

Get Vermillion News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRML and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRML vs. The Competition

Export

Metric	Vermillion	Diagnostic Substances Industry	Medical Sector	NASDAQ Exchange
Market Cap	$29.21M	$321K	$6.25B	$11.77B
Dividend Yield	N/A	N/A	2.74%	5.26%
P/E Ratio	-1.76	N/A	29.25	27.07
Price / Sales	6.43	0.08	504.68	73.47
Price / Cash	N/A	N/A	43.30	53.90
Price / Book	3.33	N/A	9.67	6.69
Net Income	-$15.24M	-$6.86M	$3.55B	$332.64M

Vermillion Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRML Vermillion	N/A	$0.30 +6.8%	N/A	N/A	$29.21M	$4.54M	N/A	43	Gap Up
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	$10K	$8.13K	N/A	10
VANI Vivani Medical	2.2487 of 5 stars	$1.36 +1.5%	$3.50 +157.4%	N/A	$115.56M	N/A	N/A	20	News Coverage Upcoming Earnings
CO Global Cord Blood	N/A	$0.95 flat	N/A	N/A	$115.53M	$1.24B	1.49	1,202	News Coverage
NYXH Nyxoah	2.2178 of 5 stars	$3.00 +1.7%	$9.33 +211.1%	N/A	$114.34M	$11.33M	N/A	110	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRML) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vermillion (VRML) Competitors

VRML vs. NAVB, VANI, CO, NYXH, and PEPG

How does Vermillion compare to Navidea Biopharmaceuticals?

Summary

How does Vermillion compare to Vivani Medical?

Summary

How does Vermillion compare to Global Cord Blood?

Summary

How does Vermillion compare to Nyxoah?

Summary

How does Vermillion compare to PepGen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRML vs. The Competition

Vermillion Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vermillion (VRML) Competitors

VRML vs. NAVB, VANI, CO, NYXH, and PEPG

How does Vermillion compare to Navidea Biopharmaceuticals?

Summary

How does Vermillion compare to Vivani Medical?

Summary

How does Vermillion compare to Global Cord Blood?

Summary

How does Vermillion compare to Nyxoah?

Summary

How does Vermillion compare to PepGen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRML vs. The Competition

Vermillion Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools